This site is intended for health professionals only
Saturday 15 December 2018
Share |

Topic: janssen

May 4, 2018
The NICE decision will result in quicker access for patients to the first selective IL-23 inhibitor

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the UK’s National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Determination (FAD) recommending Tremfya® (guselkumab) for treatment of adults with moderate to severe plaque psoriasis.1
 
The NICE recommendation states that guselkumab is recommended as an option for treating plaque psoriasis in adults, only if:

February 19, 2018
New data from VOYAGE 2 trial shows high efficacy response rates were achieved with continuous guselkumab treatment versus withdrawal

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving Tremfya® (guselkumab), who achieved at least a 90% improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.1

February 9, 2018
Phase III SPARTAN data showed apalutamide improved median metastasis-free survival by over two years compared to placebo

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that it has submitted a Marketing Authorisation Application to the European Medicines Agency (EMA) for apalutamide, an investigational, next generation oral androgen receptor (AR) inhibitor for the treatment of patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).

November 2, 2017
Late-breaking data demonstrate rapid improvement in patient-reported symptoms in patients intolerant or refractory to anti-TNF treatment

Janssen has presented new late-breaking data from UNITI-1 assessing Crohn's disease symptom improvement in patients during the first 2 weeks after an intravenous (IV) infusion dose of Stelara®(ustekinumab).1

The data presented at the 25th United European Gastroenterology Week (UEGW 2017) showed that patient-reported symptom improvement began as early as day 1 post ustekinumab IV infusion and was observed consistently at day 8 and beyond when compared with placebo.1

September 18, 2017
More than 80% of patients receiving guselkumab, including patients transitioned from HUMIRA® (adalimumab) to the anti-interleukin (IL)-23 monoclonal antibody, demonstrated PASI 90 and IGA 0/1 scores at week 100

Janssen Research & Development has presented new longer-term data from the open-label extension of the VOYAGE 1 trial demonstrating consistent rates of skin clearance with guselkumab treatment through week 100 among patients with moderate to severe plaque psoriasis receiving the subcutaneously administered anti-interleukin (IL)-23 monoclonal antibody.1

June 15, 2017
Sirukumab Phase III data presented at the Annual European Congress of Rheumatology (EULAR) 2017 also show significant improvement in quality of life measures

Janssen-Cilag International NV has announced long-term results from SIRROUND-T, a pivotal Phase III study that showed sirukumab improved the signs and symptoms of moderately to severely active rheumatoid arthritis (RA) through 52 weeks of treatment in adult patients with an inadequate response and/or intolerance to anti-tumour necrosis factor (TNF)-alpha treatments.1

May 5, 2017
NICE recommendations are in line with the licensed indication for ustekinumab, speeding up access for patients with moderately to severely active Crohn’s disease

Janssen has announced that the National Institute for Health and Care Excellence (NICE) has recommended Stelara® (ustekinumab) in its Final Appraisal Determination (FAD) as a treatment option for adult patients with moderately to severely active Crohn’s disease, who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNF alpha inhibitor or have medical contraindications to such therapies.1

November 17, 2016
The first specific anti-interleukin-23 monoclonal antibody to demonstrate significant Improvement in signs and symptoms of active psoriatic arthritis.

Janssen-Cilag International announced positive efficacy and safety results from a Phase 2 study investigating guselkumab, an anti-interleukin (IL)-23 monoclonal antibody administered by subcutaneous injection, for the treatment of active psoriatic arthritis.

January 18, 2016
C-level leaders from GSK, Novartis and Lilly have recently aligned in an effort to set out a new minimum standard or performance from their respective companies

C-level leaders from GSK, Novartis and Lilly have recently aligned in an effort to set out a new minimum standard or performance from their respective companies. They will announce their intentions at the eyeforpharma Barcelona Summit where a ‘new business plan’ for the industry comprising collaboration, culture and customer-centricity will be proposed.

Speaking ahead of the conference, David Epstein, CEO Pharmaceuticals, Novartis stressed a personal commitment: